Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
12/02/2016 12/05/2016 12/06/2016 12/07/2016 12/08/2016 Date
237.6(c) 239(c) 239.9(c) 243(c) 243.8(c) Last
4 592 164 4 142 497 4 449 172 7 002 210 4 525 323 Volume
+0.72% +0.59% +0.38% +1.29% +0.33% Change
More quotes
Financials ( DKK)
Sales 2016 111 925 M
EBIT 2016 48 801 M
Net income 2016 38 060 M
Finance 2016 12 285 M
Yield 2016 2,93%
Sales 2017 115 935 M
EBIT 2017 49 881 M
Net income 2017 39 489 M
Finance 2017 14 143 M
Yield 2017 3,13%
P/E ratio 2016 16,17
P/E ratio 2017 15,26
EV / Sales2016 4,26x
EV / Sales2017 4,10x
Capitalization 489 053 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
12/13Presentation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
01:03a NOVO NORDISK A/S : Smithfield chamber, residents oppose jail
12/08 NOVO NORDISK A/S : Patient Entrepreneur Brianna Wolin of Find Your Ditto Selecte..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/05 NOVO NORDISK A/S : NovoSeven resolved 96.5% of bleeds when initiated within one ..
12/05 NOVO NORDISK A/S : Xultophy demonstrates similar glucose control with reduced ri..
12/05 NOVO NORDISK A/S : files for regulatory approval of once-weekly semaglutide in t..
12/05 NOVO NORDISK A/S : - Share repurchase programme
12/05 NOVO NORDISK A/S : NovoSeven® resolved 96.5% of bleeds when initiated within one..
12/02 NOVO NORDISK A/S : Xultophy® demonstrates similar glucose control with reduced r..
12/02 NOVO NORDISK A/S : Xultophy Demonstrates Similar Glucose Control with Reduced Ri..
More news
Sector news : Pharmaceuticals - NEC
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/07 ET TU, DONALD? DRUGS DIVE : What's Going On, And What's Next
12/06 SNIPPET ROUNDUP : Deals For Boston And Astra; Data For Novo; An Approval For Bio..
12/05 Novo submits U.S. marketing application for long-acting diabetes med semaglut..
12/02 FDA OKs CV risk reduction claim for Lilly and BI's diabetes med Jardiance
12/01 GILEAD SCIENCES : Waiting For NASH Or For Acquisitions?
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 278  DKK
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-40.59%70 980
JOHNSON & JOHNSON8.16%302 251
ROCHE HOLDING LTD.-19.14%190 015
PFIZER INC.-2.23%189 272
NOVARTIS AG-20.05%178 826
MERCK & CO., INC.13.71%165 594
More Results